Author

Peter H. Bacher

Observed names: Bacher, P, P Bacher, P. Bacher, Peter Bacher, Peter Bacher

Observed institutions: Northwestern University, Rush University Medical Center, Loyola University Medical Center, Loyola University Chicago, Pontifícia Universidade Católica do Rio de Janeiro, AbbVie (United States), University of Chicago, Abbott (United States), Sanofi (United States), Loyola Medicine, Rush University, Freie Universität Berlin, University of Missouri

OpenAlex ID: A5069282990

Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome

2006 · George Bakris, Mark Molitch, et al. · Diabetes Care · 183

Verapamil-sustained release–based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: An INternational VErapamil SR-Trandolapril (INVEST) substudy

2008 · Sripal Bangalore, Franz H. Messerli, et al. · American Heart Journal · 53

Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin–sodium) in pediatric patients

2003 · Patricia Massicotte, Jim A Julian, et al. · Thrombosis Research · 47

Decreased Prevalence of Heparin-Induced Thrombocytopenia with Low-Molecular-Weight Heparin and Related Drugs

2004 · Jeanine M. Walenga, Walter P. Jeske, et al. · Seminars in Thrombosis and Hemostasis · 45

36-Month Treatment Experience of Two Doses of Leuprolide Acetate 3-Month Depot for Children With Central Precocious Puberty

2014 · Peter A. Lee, Karen Klein, et al. · The Journal of Clinical Endocrinology & Metabolism · 43

Risk factor assessment for new onset diabetes: literature review

2008 · George Bakris, Jack Stockert, et al. · Diabetes Obesity and Metabolism · 36

Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies

2002 · Sarfraz Ahmad, Sylvia Haas, et al. · Thrombosis Research · 33

Effects of Calcium Channel Blockers on Proteinuria in Patients With Diabetic Nephropathy

2008 · Robert D. Toto, Min Tian, et al. · Journal of Clinical Hypertension · 27

Safety and tolerability of intermittent androgen deprivation therapy: A literature review

2012 · Damian Gruca, Peter Bacher, et al. · International Journal of Urology · 23

Reversal of Diuretic‐Associated Impaired Glucose Tolerance and New‐Onset Diabetes: Results of the STAR‐LET Study

2008 · George Bakris, Mark Molitch, et al. · Journal of the CardioMetabolic Syndrome · 23

Tolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial

2008 · Aldo P Maggioni, Ian Caterson, et al. · Journal of Cardiovascular Pharmacology · 22

Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide.

1993 · D D Callas, D A Hoppensteadt, et al. · PubMed · 22

Beractant and poractant alfa in premature neonates with respiratory distress syndrome: a systematic review of real-world evidence studies and randomized controlled trials

2020 · Manuel Sánchez Luna, Peter Bacher, et al. · Journal of Perinatology · 21

PDF

Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin

1994 · Demetra Callas, Peter Bacher, et al. · Thrombosis Research · 21

The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model

1992 · P. Bacher, D. Welzel, et al. · Thrombosis Research · 21

Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation

2016 · Peter A. Lee, Margaret Luce, et al. · Journal of Pediatric Endocrinology and Metabolism · 20

Evaluation of Hemostatic and Fibrinolytic Alterations Associated with Daily Administration of Low-Molecular-Weight Heparin for a 12-Week Period

1995 · Blazej Lojewski, Peter Bacher, et al. · Seminars in Thrombosis and Hemostasis · 16

Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate

2018 · Karen O. Klein, Sanja Dragnic, et al. · Journal of Pediatric Endocrinology and Metabolism · 15

Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs

1992 · Jawed Fareed, Peter Bacher, et al. · Progress in Cardiovascular Diseases · 15

A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty.

2001 · E D Grassman, F Leya, et al. · PubMed · 14

Drug-Induced Alterations of Hemostasis and Fibrinolysis

1992 · Jawed Fareed, Debra Hoppenstedt, et al. · Hematology/Oncology Clinics of North America · 13

Modulation of endothelial and platelet function by a polydeoxyribonucleotide derived drug “defibrotide”. A dual mechanism in the control of vascular pathology

1993 · Peter Bacher, Gisela Kindel, et al. · Thrombosis Research · 11

Sustained Release of Tissue Factor Following Thrombosis of Lower Limb Trauma

2014 · Jeanine M Walenga, Phoebe C Kaiser, et al. · Clinical and Applied Thrombosis/Hemostasis · 10

PDF

Studies on the Thrombogenic Effects of Recombinant Tissue Factor

1995 · Demetra Callas, Peter Bacher, et al. · Seminars in Thrombosis and Hemostasis · 10

The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models

1993 · Peter Bacher, Jeanine M. Walenga, et al. · Thrombosis Research · 10

Works count: 49

Citation count: 788

H-index: 16

I10-index: 25